1. Home
  2. TECH vs BPMC Comparison

TECH vs BPMC Comparison

Compare TECH & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECH
  • BPMC
  • Stock Information
  • Founded
  • TECH 1976
  • BPMC 2008
  • Country
  • TECH United States
  • BPMC United States
  • Employees
  • TECH N/A
  • BPMC N/A
  • Industry
  • TECH Biotechnology: Biological Products (No Diagnostic Substances)
  • BPMC Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECH Health Care
  • BPMC Health Care
  • Exchange
  • TECH Nasdaq
  • BPMC Nasdaq
  • Market Cap
  • TECH 7.8B
  • BPMC 8.3B
  • IPO Year
  • TECH 1989
  • BPMC 2015
  • Fundamental
  • Price
  • TECH $53.94
  • BPMC $129.32
  • Analyst Decision
  • TECH Buy
  • BPMC Buy
  • Analyst Count
  • TECH 12
  • BPMC 20
  • Target Price
  • TECH $70.00
  • BPMC $127.82
  • AVG Volume (30 Days)
  • TECH 1.9M
  • BPMC 3.3M
  • Earning Date
  • TECH 08-06-2025
  • BPMC 07-31-2025
  • Dividend Yield
  • TECH 0.59%
  • BPMC N/A
  • EPS Growth
  • TECH N/A
  • BPMC N/A
  • EPS
  • TECH 0.83
  • BPMC N/A
  • Revenue
  • TECH $1,208,770,000.00
  • BPMC $562,121,000.00
  • Revenue This Year
  • TECH $7.07
  • BPMC $44.46
  • Revenue Next Year
  • TECH $5.72
  • BPMC $32.78
  • P/E Ratio
  • TECH $65.29
  • BPMC N/A
  • Revenue Growth
  • TECH 4.72
  • BPMC 99.19
  • 52 Week Low
  • TECH $46.01
  • BPMC $73.04
  • 52 Week High
  • TECH $83.62
  • BPMC $129.49
  • Technical
  • Relative Strength Index (RSI)
  • TECH 59.94
  • BPMC 76.79
  • Support Level
  • TECH $50.97
  • BPMC $128.06
  • Resistance Level
  • TECH $55.53
  • BPMC $129.49
  • Average True Range (ATR)
  • TECH 2.07
  • BPMC 0.27
  • MACD
  • TECH 0.24
  • BPMC -0.97
  • Stochastic Oscillator
  • TECH 77.60
  • BPMC 87.41

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Share on Social Networks: